FMC’s Rimisoxafen Becomes First-Ever Dual Mode of Action Herbicide Classified by HRAC
24 February 2026, Washington: FMC Corporation has announced that the Herbicide Resistance Action Committee (HRAC) has classified rimisoxafen as a dual mode of action herbicide under HRAC Groups 12 and 32. According to the company, this marks the first time in HRAC’s history that a herbicide has received a dual mode of action classification.
The classification recognises rimisoxafen’s ability to inhibit two biochemical pathways in weeds simultaneously: phytoene desaturase (PDS) and solanesyl diphosphate synthase (SDPS). By targeting both pathways, the molecule is designed to reduce the likelihood of weed survival and adaptation, offering an additional tool for resistance management programmes.
“HRAC’s historic classification of rimisoxafen validates the breakthrough nature of this technology,” said Seva Rostovtsev, Executive Vice President and Chief Technology Officer at FMC. “Studies show this molecule delivers control of palmer amaranth and waterhemp, giving farmers an effective solution against weeds that have become resistant to multiple herbicide classes. This is the kind of innovation growers need to protect their crops and their livelihoods.”
Herbicide resistance continues to expand across major cropping systems worldwide. Palmer amaranth, considered among the most economically damaging weed species in several production regions, has developed resistance to eight different herbicide modes of action. FMC states that rimisoxafen’s dual mode of action creates a higher barrier to resistance development compared to herbicides with a single target site.
The company is positioning rimisoxafen primarily for use in broadacre crops including corn, soybean, cereals, pulses and sunflower, with a focus on controlling resistant and difficult-to-manage broadleaf weeds.
Rimisoxafen was discovered by FMC scientists at the company’s Stine Research Center. It is the third novel herbicide active ingredient developed by FMC for regulatory submission in recent years, following Isoflex® active and Dodhylex™ active. FMC expects to begin submitting regulatory dossiers for rimisoxafen in key markets starting in 2026 as it moves toward commercialisation in global markets.
Also Read: Bayer Launches Multi-Crop Seed Brand ‘newgold®’ to Help Farmers Tap the Low-Carbon Biofuel Economy
Global Agriculture is an independent international media platform covering agri-business, policy, technology, and sustainability. For editorial collaborations, thought leadership, and strategic communications, write to pr@global-agriculture.com
